Enhanced uptake and transport of (+)-catechin and (-)-epigallocatechin gallate in niosomal formulation by human intestinal caco-2 cells

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 2157-2165

  Song, Qinxin ^a,b,c   Li, Danhui ^c   Zhou, Yongzhi ^c   Yang, Jie ^a   Yang, Wanqi ^a   Zhou, Guohua ^b   Wen, Jingyuan ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bioavailability; Formulation; Niosomes; Stability

Indexed keywords

ADENOSINE TRIPHOSPHATE; CATECHIN; EPIGALLOCATECHIN GALLATE; GLYCOPROTEIN; GLYCOPROTEIN P INHIBITOR; NIOSOME; SODIUM AZIDE; VERAPAMIL; VERLUKAST; LIPOSOME; NANOCAPSULE;

ARTICLE; CACO 2 CELL LINE; DRUG ABSORPTION; DRUG TRANSPORT; ENCAPSULATION; HUMAN; HUMAN CELL; INTESTINE CELL; INTESTINE EPITHELIUM; MEMBRANE TRANSPORT; MONOLAYER CULTURE; PROTEIN STABILITY; PROTEIN TRANSPORT; TEMPERATURE DEPENDENCE; TEMPERATURE SENSITIVITY; ANALOGS AND DERIVATIVES; CHEMISTRY; INTESTINE ABSORPTION; METABOLIC CLEARANCE RATE; PHYSIOLOGY; ULTRASTRUCTURE; UPREGULATION;

CACO-2 CELLS; CATECHIN; HUMANS; INTESTINAL ABSORPTION; LIPOSOMES; METABOLIC CLEARANCE RATE; NANOCAPSULES; UP-REGULATION;

EID: 84900414320     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S59331     Document Type: Article

References (25)

1. Fujiki H, Suganuma M. Green tea: an effective synergist with anticancer drugs for tertiary cancer prevention. Cancer Lett. 2012;324(2): 119-125.
2. Grassi D, Desideri G, Di Giosia P, et al. Tea, flavonoids, and cardiovascular health: endothelial protection. Am J Clin Nutr. 2013;98(Suppl 6): 1660S-1666S.
3. Gu JW, Makey KL, Tucker KB, et al. EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression. Vasc Cell. 2013;5(1):9.
4. Yu Y, Deng Y, Lu BM, Liu YX, Li J, Bao JK. Green tea catechins: a fresh flavor to anticancer therapy. Apoptosis. 2014;19(1):1-18.
5. Baba S, Osakabe N, Natsume M, Muto Y, Takizawa T, Terao J. In vivo comparison of the bioavailability of (+)-catechin, (-)-epicatechin and their mixture in orally administered rats. J Nutr. 2001;131(11):2885-2891.
6. Henning SM, Choo JJ, Heber D. Nongallated compared with gallated flavan-3-ols in green and black tea are more bioavailable. J Nutr. 2008;138(8):1529S-1534S.
7. Chow HH, Hakim IA, Vining DR, et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res. 2005; 11(12):4627-4633.
8. Peters CM, Green RJ, Janle EM, Ferruzzi MG. Formulation with ascorbic acid and sucrose modulates catechin bioavailability from green tea. Food Res Int. 2010;43(1):95-102.
9. Dube A, Ng K, Nicolazzo JA, Larson I. Effective use of reducing agents and nanoparticle encapsulation in stabilizing catechins in alkaline solution. Food Chem. 2010;122(3):662-667.
10. Caddeo C, Teskac K, Sinico C, Kristl J. Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int J Pharm. 2008;363(1-2):183-191.
11. Mahale NB, Thakkar PD, Mali RG, Walunj DR, Chaudhari SR. Niosomes: novel sustained release nonionic stable vesicular systems - an overview. Adv Colloid Interface Sci. 2012;183-184:46-54.
12. Sambuy Y, De Angelis I, Ranaldi G, Scarino ML, Stammati A, Zucco F. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol. 2005;21(1):1-26.
13. Li D, Martini N, Wu Z, Wen J. Development of an isocratic HPLC method for catechin quantification and its application to formulation studies. Fitoterapia. 2012;83(7):1267-1274.
14. Junyaprasert VB, Singhsa P, Suksiriworapong J, Chantasart D. Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid. Int J Pharm. 2012;423(2):303-311.
15. Lun Su Y, Leung LK, Huang Y, Chen ZY. Stability of tea theaflavins and catechins. Food Chem. 2003;83:189-195.
16. Han DW, Matsumura K, Kim B, Hyon SH. Time-dependent intracellular trafficking of FITC-conjugated epigallocatechin-3-O-gallate in L-929 cells. Bioorg Med Chem. 2008;16(22):9652-9659.
17. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150(1):76-85.
18. Vaidyanathan JB, Walle T. Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm Res. 2001;18(10):1420-1425.
19. Hong J, Lu H, Meng X, Ryu JH, Hara Y, Yang CS. Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells. Cancer Res. 2002;62(24):7241-7246.
20. Zhou S, Feng X, Kestell P, Paxton JW, Baguley BC, Chan E. Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. Eur J Pharm Sci. 2005;24(5):513-524.
21. Marianecci C, Paolino D, Celia C, Fresta M, Carafa M, Alhaique F. Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fibroblasts. J Control Release. 2010;147(1):127-135.
22. Di Marzio L, Marianecci C, Cinque B, et al. pH-sensitive non-phospholipid vesicle and macrophage-like cells: binding, uptake and endocytotic pathway. Biochim Biophys Acta. 2008;1778(12):2749-2756.
23. Vaidyanathan JB, Walle T. Cellular uptake and efflux of the tea flavonoid (-)epicatechin-3-gallate in the human intestinal cell line Caco-2. J Pharmacol Exp Ther. 2003;307(2):745-752.
24. Collett A, Higgs NB, Sims E, Rowland M, Warhurst G. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J Pharmacol Exp Ther. 1999;288:171-178.
25. Rojanasakul Y, Liaw J, Robinson JR. Mechanisms of action of some penetration enhancers in the cornea: laser scanning confocal microscopic and electrophysiology studies. Int J Pharm. 1990;66(1-3):131-142.